Thieler Law Corp advises investors with losses exceeding $100,000 of the May 2, 2016 lead plaintiff deadline in a class action lawsuit filed against PTC Therapeutics Inc (NASDAQ: PTCT) (“PTC” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased PTC Therapeutics Inc securities between May 6, 2014 and February 23, 2016, have until May 2, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased PTC Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that PTC Therapeutics NDA for Translarna that it submitted to the FDA was not sufficiently complete to permit a substantive review of the application; that, as such, the application would not be reviewed nor approved by the FDA; that the impending non-approval of the NDA would have a negative material impact on the Company’s operations and prospects; as a result of the foregoing Defendants’ statements about PTC Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On February 23, 2016, PTC Therapeutics Inc revealed receipt of a Refuse to File letter from the United States Food and Drug Administration regarding PTC Therapeutics New Drug Application for the drug Translarna, an oral protein restoration therapy designed to treat a form of muscular dystrophy. The FDA states in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review.

Following this news, NASDAQ: PTCT shares declined more than 55% on intraday trading.

If you were negatively impacted by your investment in PTC Therapeutics Inc securities between May 6, 2014 and February 23, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185